Digene Corp. (DIGE)

Digene Corporation engages in the development, manufacture, and marketing of its proprietary gene-based diagnostic tests for the screening, monitoring, and diagnosis of human diseases with a focus on women’s cancers and infectious diseases worldwide. The company primarily offers human papillomavirus (HPV) testing products, which are FDA-approved tests for the detection of HPV, are a reproducible, objective test for the primary cause of cervical cancer. Its primary product is The Digene HPV Test, a FDA-approved test for HPV, the primary cause of cervical cancer. The company also provides a diagnostic test products portfolio that includes gene-based tests for the detection of other sexually transmitted infections, including chlamydia and gonorrhea, as well as tests for blood viruses and hepatitis B virus. In addition, it develops and sells to clinical laboratories the equipment, instrumentation, and accessories used to perform clinical specimen testing with its diagnostic tests. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

For the three months ended 30 September 2006, Digene Corporation's revenues increased 38% to $46.1M. Net income totaled $5.1M, up from $1.3M. Revenues reflect increased turnover as a result of higher sales of Human Papillomavirus test products due to increased sales in United States and higher other revenue. Net income also reflects improved operating margins, increased interest income and lower minority interest paid.